iRhythm Technologies, Inc.
NASDAQ•IRTC
CEO: Mr. Quentin S. Blackford
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 2016-10-20
iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.
Contact Information
Market Cap
$3.65B
P/E (TTM)
-81.8
26.6
Dividend Yield
--
52W High
$212.00
52W Low
$92.52
52W Range
Rank62Top 92.6%
1.9
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 1.9 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q4 2025 Data
Revenue
$208.89M+0.00%
4-Quarter Trend
EPS
$0.17+0.00%
4-Quarter Trend
FCF
$14.49M+0.00%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
Revenue Growth Strong Net revenue reached $747.1M USD, marking 26% increase driven by higher service volumes and Zio AT adoption.
Gross Profit Margin Expansion Gross profit reached $527.3M USD, showing 29% growth due to better pricing and volume mix.
Net Loss Significantly Reduced Net loss narrowed to $(44.6)M USD, reflecting a substantial 61% reduction compared to prior year.
IPR&D Expense Reverts Acquired IPR&D expense dropped 91% to $3.0M USD following 2024 BioIntelliSense license charge.
Risk Factors
Medicare Reimbursement Risk Reimbursement highly regulated; failure to comply with remote test rules risks penalties and revenue loss.
Competitive Monitoring Market Remote monitoring market is highly competitive; competitors developing more effective devices could reduce opportunities.
Significant Debt Load Servicing $661.3M USD in 2029 Notes requires substantial cash flow, impacting future financial flexibility.
Ongoing Legal Proceedings Company faces ongoing patent litigation risks; adverse outcomes could result in damages or prohibit product use.
Outlook
Expand Core Monitoring Market Strategy focuses on penetrating core market, expanding utilization across cardiology and primary care specialties.
Adjacent Clinical Opportunities Pursuing proactive monitoring in adjacent areas like Sleep Apnea and Heart Failure using existing platform capabilities.
Advance Product Portfolio Investing in next-gen MCT device, 510(k) submitted Q3 2025, enhancing detection algorithms and insights.
International Expansion Focus Selectively expanding internationally in geographies with established regulatory pathways and reimbursement progression.
Peer Comparison
Revenue (TTM)
$11.70B
$5.10B
$3.44B
Gross Margin (Latest Quarter)
100.0%
93.7%
83.8%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| AXSM | $7.98B | -43.1 | -254.1% | 35.0% |
| PCVX | $7.86B | -9.7 | -25.9% | 7.5% |
| ARWR | $7.71B | 38.1 | 36.1% | 19.5% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
9.6%
Steady Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
75%
Volatile Cash Flow
Deep Research
Next earnings:Apr 29, 2026
EPS:-
|Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data